Skip to main content

Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia

Correction to: Clinical Epigenetics (2015) 7:2, https://doi.org/10.1186/s13148-014-0034-4

Following publication of the original article [1], the authors identified an error in Fig. 2e. The correct Fig. 2 is given below.

Fig. 2
figure2

The combined effects of panobinostat and arsenic trioxide (ATO) include the differentiation of A/E9a;Nras G12D-leukemic blasts by panobinostat and induction of apoptosis by ATO. (A) Flow cytometry analysis of the cell surface expression of c-Kit; Sca1; Mac1 and Gr1 of GFP-positive tumor cells in the bone marrow of A/E9a;Nras G12D tumor-bearing mice treated for 5 days with either panobinostat (pan; 25 mg/kg) or panobinostat combined with ATO (2.5 mg/kg). (n = 3; data are expressed as mean plus SEM; *P <0.05, **P <0.001) (B) Representative dot plots of AnnexinV-PI staining of tumor cells isolated from the bone marrow of A/E9a; NrasG12D tumor-bearing mice treated for 4 hours with either panobinostat (25 mg/kg) or ATO (2.5 mg/kg) or a combination. Numbers given are the percentage of total cell population. (C) Normalized expression of AnnexinV on tumor cells treated with vehicle, panobinostat, ATO or a combination (n = 3; data are expressed as mean plus SEM). (D) Quantification of terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) positivity as a proportion of total cell area (n = 3; *P <0.001) (E) Representative images of hematoxylin-eosin staining (H&E; upper panels) and analysis of apoptotic cells by TUNEL staining and counterstained with hematoxylin (lower panels). Staining was performed on de-calcified femurs isolated from A/E9a;Nras G12D tumor-bearing mice treated for 4 hours as indicated. Imaging was performed using 60x objective (scale bars = 50 μm).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Ricky W. Johnstone.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Salmon, J.M., Bots, M., Vidacs, E. et al. Correction to: Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. Clin Epigenet 12, 178 (2020). https://doi.org/10.1186/s13148-020-00964-9

Download citation